Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Dose-Ranging Study of Alferon® LDO [Low Dose Interferon Alfa-n3 (Human Leukocyte Derived)] in Asymptomatic HIV+ Subjects

NCT00215852 is registered in ClinicalTrials.gov with AIM ImmunoTech Inc. as lead sponsor.

NCT NCT00215852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00215852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Dose-Ranging Study of Alferon® LDO [Low Dose Interferon Alfa-n3 (Human Leukocyte Derived)] in Asymptomatic HIV+ Subjects
Lead sponsor
AIM ImmunoTech Inc.
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2005
Completion date
April 30, 2009
Enrollment
17 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections